The group's principal activities are to design, develop, manufacture and market minimally invasive human implants and medical devices for the repair and regeneration of damaged human tissue. The group developed a proprietary collagen based matrix technology, which has been clinically proven to regenerate lost or damaged tissue. This technology produces a scaffold, which promotes the natural re-growth of tissue into the implanted matrix. The group chose to initially adapt this technology in the orthopedic area, which offers a substantial unmet need and large market size.
